Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

The next generation of weight-loss drugs aim to help patients lose more weight even faster. CagriSema — developed by Novo Nordisk, the company behind Wegovy — is one example. In a trial last ...

Wegovy's potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo's stock has fallen more than 20% over the last year, and people feared ...

In its earnings release, Novo Nordisk outlined its plans to conduct a new phase 3 trial in 2025 to further explore CagriSema’s weight-loss potential. The results from the second pivotal phase 3 ...

CagriSema combines semaglutide, the active ingredient in Wegovy that mimics gut hormone GLP-1, with a separate molecule called cagrilintide that mimics pancreatic hormone amylin. One participant in ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...